Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Taurochenodeoxycholate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 3/20 | 0.70 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.70 |
| ▸ | NR3C1 known ✓ | P04150 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.84 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.84 |
| ▸ | SLC10A2 | Q12908 | 3/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.84 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.84 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
| ▸ | SLC10A1 | Q14973 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurochenodeoxycholate SCHEMBL9222712 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL60947 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL29461502 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL29481129 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL20261732 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL30341854 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL60964 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL10695689 | 1.00 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL9068987 | 0.98 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 | |
| Taurochenodeoxycholate SCHEMBL9070059 | 0.98 | GPBAR1 (0.84) | GPBAR1NR1H4SLC10A2ABCB11ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119970751-A | Medicine for preventing and relieving toxicity of alternariol and application thereof | 上海市疾病预防控制中心 | 2025-05-13 | — | — | CN | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | claimed |
| CN-117241780-A | Biological delivery system | 帕帝塞拉公司 | 2023-12-15 | — | — | CN | claimed |
| EP-4259099-A1 | BIOLOGICAL DELIVERY SYSTEMS | Particella, Inc. (US) | 2023-10-18 | — | — | EP | claimed |
| US-20230181500-A1 | Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery | AMPHASTAR PHARMACEUTICALS INC (US) | 2023-06-15 | — | — | US | claimed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | claimed |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4673468-A1 | ANTI-CD2 ANTIBODIES FOR AMYOTROPHIC LATERAL SCLEROSIS | Zelarion Malta Limited (MT) | 2026-01-07 | — | — | EP | disclosed |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OPKO BIOLOGICS LTD. (IL) | 2025-10-23 | — | — | US | disclosed |
| US-12447192-B1 | Stable cannabinoid-comprising nanoemulsions and methods of using the same | SGN NANOPHARMA INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12403192-B2 | Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250205165-A1 | THERAPEUTIC VESICLES AND METHODS OF PROCESSING THE SAME | BEIJING THERAXYTE BIOSCIENCE CO. LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-1817048-B2 | STABLE FORMULATIONS OF INSULINOPTROPIC PEPTIDES | NOVO NORDISK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| WO-2022132678-A1 | BIOLOGICAL DELIVERY SYSTEMS | DNALITE THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220175714-A1 | USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENT | SOOCHOW UNIVERSITY (CN) | 2022-06-09 | — | — | US | disclosed |
| CN-114592027-A | Method for preparing tauroursodeoxycholic acid by two-step method | 北京岳达生物科技有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220105172-A1 | HERPES SIMPLEX VIRUS NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| EP-2721391-B1 | SOLUTION AND METHOD FOR HISTOPROCESSING OF BIOLOGICAL SAMPLES | ROCHE DIAGNOSTICS HEMATOLOGY INC (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022023545-A2 | PHARMACEUTICAL COMBINATION COMPRISING GLYCOLIC ACID AND L-ALANINE | PAN MONTOJO FRANCISCO (DE) | 2022-02-03 | — | — | WO | disclosed |
| EP-0273469-A1 | Oral pharmaceutical compositions with sustained release | Gipharmex S.p.A. (IT) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181500-A1 | Naloxone Pharmaceutical Formulations for Intranasal (IN) Delivery | SLC10A1, SLC10A2, OPRK1 | CA1 2593/4885CA2 2052/4885NR3C1 325/4885 |
| US-20250326814-A1 | MODIFIED OXYNTOMODULIN AND METHODS OF USE THEREOF | OGFRL1, OXGR1, THOP1 | CA1 3452/4885CA2 2833/4885NR3C1 669/4885 |
| US-20260007731-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME | CD14, CD47, MYD88 | CA1 3075/4885CA2 4170/4885NR3C1 3949/4885 |
| US-12447192-B1 | Stable cannabinoid-comprising nanoemulsions and methods of using the same | CNR2, CNR1, NCSTN | CA1 2067/4885CA2 1384/4885NR3C1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.